Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LONDON, Sept. 07, 2016 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Wednesday, 14 September 2016 at 9:55 a.m. EDT.
A live audio webcast of the presentations will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentations.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | (Today) +44 20 3727 1000 |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |
| FTI Consulting (Media Enquiries) | |
| Ben Atwell / Simon Conway | + 44 20 3727 1000 |
| FleishmanHillard (U.S. Media) | |
| Paddi Hurley / Adam Silverstein | 212 453 2382 / 917 697 9313 |
